At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 10 enrolled
Drug / intervention
Adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis
In Brief
A Phase 3 clinical trial evaluating Adalimumab for Generalized Pustular Psoriasis (GPP) and 2 related conditions. Completed, enrolled 10 participants.
Detailed Summary
The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently approved treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Pustular Psoriasis (GPP), Adalimumab, Japanese
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartSep 2015
Primary CompletionSep 2016
Study CompletionJul 2017
TodayJul 2026
First PostedAug 26, 2015
Enrollment StartSep 28, 2015
Primary CompletionSep 15, 2016
Study CompletionJul 20, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.8 years ago
Interventions
Adalimumabdrug
Adalimumab pre-filled syringe, administered by subcutaneous injection